Merger Control Explained: How Antitrust Clearance Decides Whether a Deal Closes — the CMA, EU and US Regimes Compared
Michael King, PE Investment Manager · 10 min read ·
- Merger control is the gate between signing and closing. The buyer and seller sign the SPA; the deal only completes once the relevant competition authorities have cleared it — a gap that runs from a few weeks to well over a year on a contested case
- The substantive question is the same everywhere: does the combination substantially lessen competition (SLC in the UK and US) or significantly impede effective competition (SIEC in the EU)? The jurisdictional thresholds that decide who reviews it are not
- The UK is the outlier. CMA notification is voluntary and non-suspensory — a deal can legally complete before clearance — whereas the EU and US are mandatory and suspensory: file, wait, and do not close until cleared. That single distinction reshapes deal timetables and risk
- The antitrust risk is priced, not assumed away. It lives in the long-stop date, the conditions precedent, the reverse break fee the buyer pays if clearance fails, and — for anyone trading the stock — the merger-arb spread, which is a live probability of the deal closing, not a rounding error
Merger Control Is the Gate Between Signing and Closing
Merger control is the regime under which a competition authority reviews an acquisition before it can complete, to decide whether the combined business would harm competition in a market. A signed deal is not a closed deal: between the two sits a review that can take 40 working days or two years, and that can force a divestiture or block the transaction outright. For a large cross-border deal, clearance is routinely the longest and least controllable item on the timetable — the thing that turns a three-month completion into a fifteen-month one.
This is the workstream that sits behind almost every headline about a deal “collapsing over regulatory concerns.” Understanding it is what separates a candidate who can describe the M&A process from one who understands why deals actually fail to close.
Three Regimes, One Question: Does the Deal Lessen Competition?
Every major regime asks the same substantive question and answers it with a different acronym. The UK and US apply a substantial lessening of competition (SLC) test; the EU applies a significant impediment to effective competition (SIEC) test. In practice they converge on the same worries: horizontal overlap between competitors, vertical foreclosure up or down a supply chain, and — increasingly — the “killer acquisition,” where an incumbent buys a nascent rival before it becomes a threat.
What differs sharply is jurisdiction — the turnover and market-share tests that decide which authority gets to review the deal at all. A single mid-market European deal can be notifiable in three, five, or a dozen countries at once, and the binding constraint is whichever regime is slowest.
| Regime | Key jurisdictional threshold | Notification | Substantive test |
|---|---|---|---|
| UK — CMA | Target UK turnover > £100M, or the merging parties supply 25%+ of a UK market and the deal increases that share. A new limb also catches deals where one party has a 33%+ UK share of supply and > £350M UK turnover | Voluntary, non-suspensory | SLC |
| EU — Commission | Combined worldwide turnover > €5bn and EU-wide turnover of each of at least two parties > €250M | Mandatory, suspensory | SIEC |
| US — FTC/DOJ (HSR) | Deal size > $126.4M (2025 threshold, indexed annually) | Mandatory, suspensory | SLC (Clayton Act §7) |
The UK turnover threshold moved from £70M to £100M on 1 January 2025 under the Digital Markets, Competition and Consumers Act, alongside the new 33% / £350M limb designed to catch acquisitions with no horizontal overlap at all. Treat every figure here as the current statutory benchmark, not a permanent one — these thresholds are legislated and revised, and the US size-of-transaction test is re-indexed each year.
The UK Is the Odd One Out: Voluntary and Non-Suspensory
The single most important thing to know about UK merger control is that it does not work like the others. There is no obligation to notify the CMA, and a deal can legally complete before — or without ever — being cleared. On paper that sounds permissive. In practice it is a trap for the careless, because the CMA can “call in” a completed merger and investigate it retrospectively for up to four months after it comes to the authority's attention.
The lever the CMA uses is the initial enforcement order (IEO): once it starts looking, it can freeze integration — forbidding the buyer from combining the two businesses — while it reviews. A buyer that closed and started merging operations can be ordered to hold the target separate, and in the worst case unwind a deal it has already completed. So sophisticated parties on any deal with a real overlap notify voluntarily and wait, precisely to avoid that risk. The voluntary regime is voluntary the way skipping the diligence is optional.
Phase 1 Versus Phase 2: Where Deals Actually Die
Every regime runs a two-stage funnel. Phase 1 is a fast initial review that clears the large majority of deals; Phase 2 is a deep investigation reserved for the minority that raise a genuine competition concern. Getting waved through at Phase 1 is the goal; a Phase 2 reference is where timelines blow out and deals break.
Remedies: Structural Beats Behavioural, and Regulators Know It
When an authority finds a competition problem but does not want to block the deal, it demands remedies — conditions the parties accept to get their clearance. These split into two families, and the distinction is worth having a view on.
Structural remedies change the shape of the combined business: divest a brand, a plant, a set of contracts, or an overlapping subsidiary to a suitable buyer. They are clean, one-off, and self-policing — once the asset is sold, the concern is gone. Behavioural remedies instead constrain conduct: commitments to keep offering a product, to license on fair terms, to firewall data. They are cheaper for the buyer but require ongoing monitoring, and regulators distrust them because a promise to behave is only as good as the enforcement behind it.
The strong revealed preference of the CMA and the Commission is structural. A buyer proposing behavioural fixes to a horizontal overlap is usually negotiating from a losing position — and a deal thesis that only survives with a carved-out divestiture is a deal that has already given back part of its synergy case before it closes.
How Antitrust Risk Is Priced Into the Deal
None of this is left to fate in the contract. Merger control is one of the primary reasons the gap between signing and closing exists at all, and the SPA allocates the risk explicitly. Four mechanisms do the work, and they are standard reading in any deal with a regulatory angle.
| Mechanism | What it does |
|---|---|
| Condition precedent (CP) | Clearance is a condition to completion. No clearance, no obligation to close — the deal is contingent on the regulator, by design |
| Long-stop date | A backstop date by which all conditions must be met. If clearance is not obtained in time, either party can walk. On regulator-heavy deals this is set 12–18 months out precisely to accommodate a possible Phase 2 |
| Efforts covenant | How hard the buyer must fight for clearance — from “reasonable endeavours” up to a “hell or high water” clause obliging it to divest whatever the regulator demands. The seller wants the strongest covenant; the buyer resists it |
| Reverse break fee | A fee the buyer pays the seller if the deal fails on antitrust grounds — often 3–6% of equity value. It is the price of certainty the seller extracts for taking regulatory risk off the table |
The reverse break fee is the mirror image of the ordinary break fee a seller pays for walking away. Here the buyer is the one who might fail to deliver, so the buyer posts the fee — and its size is a direct read on how much antitrust risk both sides think the deal carries. A large reverse break fee is not generosity; it is the seller pricing the probability that the regulator says no. Where completion drags, a ticking fee can also compensate the seller for the delay itself.
The Merger-Arb Read: the Spread Is a Live Probability
Nowhere is antitrust risk priced more visibly than in the target's share price after a deal is announced. A target agreed to be bought at £10 rarely trades at £10 — it trades at some discount, say £9.40, and that 60p gap is the merger-arbitrage spread. It is not noise. It is the market's estimate of the probability the deal closes, discounted for the time to completion, and merger control is the single largest input into that probability.
Announce a clean deal with no overlap and the spread is thin — a point or two, reflecting near-certainty. Announce a horizontal merger between the number-one and number-three players in a concentrated market and the spread gaps wide, because the market is pricing a real chance of a Phase 2 reference, a forced divestiture, or an outright block. When a regulator opens a Phase 2 investigation, the spread widens on the news; when it clears, the spread collapses to the deal price. A merger-arb desk is, in effect, underwriting antitrust risk for a living.
One More Gate: Foreign Investment Review Is Not Antitrust
A frequent and revealing confusion: merger control is about competition, and it is not the only regulatory gate a deal must clear. Running in parallel is foreign direct investment (FDI) review — in the UK, the National Security and Investment Act 2021 — which screens acquisitions on national security grounds, not competitive ones.
The NSIA regime is mandatory and suspensory for deals in 17 sensitive sectors — defence, advanced computing, critical infrastructure, AI — and it can block or condition a deal that raises no competition concern whatsoever. A candidate who conflates the two is telling the interviewer they have read about deals rather than worked on them. Antitrust asks whether the market stays competitive; FDI asks whether the state is comfortable with who owns the asset. Different question, different regulator, same signing-to-closing gap.
The Verdict: Clearance Is a Deal Term, Not a Formality
The instinct of a student is to treat regulatory approval as a rubber stamp at the end of the process. The instinct of anyone who has staffed a deal is the opposite: merger control is a live commercial variable that shapes the price, the timetable, the contract and the walk-away rights from the moment the deal is conceived. The bankers model the synergies; the lawyers and economists model the clearance, and on a contested deal the second workstream is the one that decides whether the first ever matters.
The through-line is that every part of the machinery — the voluntary UK regime, the Phase 1/Phase 2 funnel, the structural remedy, the reverse break fee, the merger-arb spread — is the market and the drafters pricing the same underlying risk: that the deal, however sound the industrial logic, does not close because a regulator decides the market is better off without it. Name that risk and where it lives, and you are reading the deal the way the people in the room read it.
Take Your Preparation Further
Merger control sits at the centre of deal execution, so read it alongside the mechanics it touches. For the contractual plumbing of the signing-to-closing gap it lives in, see Conditions Precedent and the Material Adverse Change clause; for the fees that price the risk, Break Fees and Go-Shops; and for how the risk shows up in the stock, Merger Arbitrage and the Deal Spread. For the UK public-company overlay, see the Takeover Code, and for where clearance fits in the wider deal, the full M&A process.
To structure the process end to end, download the free M&A Process Cheat Sheet, and for the full set of technical interview questions and model answers — including how to talk through deal conditionality and regulatory risk under pressure — see the IB Interview Bible.
Ready for personalised feedback? Book a 1-on-1 mentoring session with an experienced IB/PE professional.
Frequently asked questions
What is merger control in M&A?
Merger control is the regime under which a competition authority — the CMA in the UK, the European Commission in the EU, the FTC or DOJ in the US — reviews an acquisition before it completes to decide whether the combined business would harm competition in a market. It sits between the signing of the deal and its closing: the parties agree terms, but the transaction only completes once the relevant authorities have cleared it. On a large cross-border deal, clearance is often the longest and least controllable item on the timetable, capable of forcing a divestiture or blocking the deal outright.
Is merger control notification mandatory in the UK?
No — and this is the key difference from most regimes. UK merger control is voluntary and non-suspensory, meaning there is no legal obligation to notify the CMA and a deal can complete before, or without, being cleared. However, the CMA can "call in" a completed merger and investigate it retrospectively, and it can impose an initial enforcement order freezing integration or even require an unwind. So on any deal with a genuine competitive overlap, sophisticated parties notify voluntarily and wait for clearance rather than risk a retrospective challenge. By contrast, the EU and US regimes are mandatory and suspensory: you must file and cannot close until clearance is granted.
What is the difference between Phase 1 and Phase 2 in a merger review?
Phase 1 is a fast initial screen that clears the large majority of deals — 40 working days at the CMA, 25 at the European Commission, a 30-day waiting period under the US HSR Act. Phase 2 is a deep investigation reserved for the minority of deals that raise a genuine competition concern: the CMA takes up to 24 weeks (extendable by 8), and the Commission takes an additional 90 working days. A Phase 2 reference (or a US "Second Request") is the inflection point where timelines blow out — it is often enough to kill a deal on its own, because few buyers will wait out the better part of a year with the outcome uncertain.
What is a reverse break fee and how does it relate to antitrust?
A reverse break fee is a fee the buyer pays the seller if the deal fails to complete on antitrust or other regulatory grounds — often in the region of 3–6% of equity value. It is the mirror image of an ordinary break fee, which a seller pays for walking away from a deal; here it is the buyer who might fail to deliver clearance, so the buyer posts the fee. Its size is a direct read on how much antitrust risk both sides believe the deal carries: a large reverse break fee means the seller is being paid meaningfully to take on the possibility that the regulator says no.
How does merger control affect the merger-arbitrage spread?
The merger-arb spread is the gap between a target’s share price after a deal is announced and the agreed offer price — for example a stock trading at £9.40 on a £10 offer. That spread is the market’s estimate of the probability the deal closes, discounted for the time to completion, and merger control is the single largest input. A clean deal with no competitive overlap trades on a thin spread; a horizontal merger between close competitors trades wide, because the market is pricing a real chance of a Phase 2 reference, a forced divestiture, or an outright block. The spread widens when a regulator opens an in-depth investigation and collapses to the deal price on clearance.